- Cash flow statements
In 2008, ExonHit's net use of cash due to operating activities was EUR 9.6 million compared to EUR 4.9 million in 2007. This difference is mainly due to the increased operating losses and to the increased Research Tax Credit line.
The equipment necessary to strengthen our service laboratory and prepare it for GLP mainly explains the capital expenditure level of EUR 1.2 million in 2008, compared to EUR 1.1 million in 2007.
Due to unfavorable market conditions, financial operations generated EUR 0.2 million in 2008, to be compared with the generation of EUR 13.3 million in 2007.
EHT Dx21, our internally developed blood diagnostic test for Alzheimer's disease (AD), is undergoing clinical validation. The clinical study EHT AD/002 initiated early in 2008 to recruit blood samples for patients suffering from AD, other dementias and controls achieved its first goal with the recruitment of 311 samples in Q3 2008. The second part of the study was initiated in January 2009 with the recruitment of 250 additional samples making the total number of samples included in the validation the largest for an array based AD blood diagnostic test.
Assuming successful clinical validation, ExonHit Therapeutics plans to launch EHT Dx21 as a Research Use Only product in the clinical trial market in Q4 2009, and in the clinical diagnostic market in a second step through a partnering model.
In February 2009, bioMerieux and ExonHit Therapeutics agreed on new
research and development plans as part of their existing collaboration to
develop blood-based cancer detection biomarkers. Both companies are jointly
pursuing their programs on colorectal and prostate cancers (respectively EHT
Dx12 and EHT Dx13) using ExonHit's next generation of human genome-wide
SpliceArray(tm) biochips for biomarker disco
|SOURCE ExonHit Therapeutics SA|
Copyright©2009 PR Newswire.
All rights reserved